Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90 Y Radioembolization with Immunotherapy in HCC

New strategies combining yttrium 90 ( 90 Y) radioembolization and immune checkpoint inhibitor therapy for treatment of advanced-stage hepatocellular carcinoma show promising safety and improved tumor response rates, with 90 Y radioembolization modulating the tumor immune microenvironment and enhancing responsiveness to immunotherapy.